Cargando…

Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity

B cell abnormalities are common in systemic lupus erythematosus (SLE), and include expansion of double negative (DN) and age-associated-like B cells (ABC-like). We aimed to investigate rituximab (RTX) effects on DN and ABC-like B-cell subsets and, when possible, also secondary effects on T cells. Fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faustini, Francesca, Sippl, Natalie, Stålesen, Ragnhild, Chemin, Karine, Dunn, Nicky, Fogdell-Hahn, Anna, Gunnarsson, Iva, Malmström, Vivianne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027571/ https://www.ncbi.nlm.nih.gov/pubmed/35464461 http://dx.doi.org/10.3389/fimmu.2022.826152

Ejemplares similares

First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis
por: Faustini, Francesca, et al.
Publicado: (2021)

Arthritis in systemic lupus erythematosus is characterized by local IL‐17A and IL‐6 expression in synovial fluid
por: Sippl, N., et al.
Publicado: (2021)

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis
por: Vallerskog, Therese, et al.
Publicado: (2006)

Occurrence and localization of FOXP3 + cells in kidney biopsies in lupus nephritis and ANCA-associated vasculitis
por: Zickert, Agneta, et al.
Publicado: (2023)

Urinary aberrations in systemic lupus erythematosus not always indicative of lupus nephritis: a cross-sectional cohort study
por: Karlsson, Linnea, et al.
Publicado: (2023)

Effector Functions of CD4+ T Cells at the Site of Local Autoimmune Inflammation—Lessons From Rheumatoid Arthritis
por: Chemin, Karine, et al.
Publicado: (2019)

IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment
por: Zickert, Agneta, et al.
Publicado: (2015)

Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus
por: Wincup, Chris, et al.
Publicado: (2022)

Antiphospholipid Antibodies in Lupus Nephritis
por: Parodis, Ioannis, et al.
Publicado: (2016)

Urine Galectin-3 binding protein reflects nephritis activity in systemic lupus erythematosus
por: Faustini, Francesca, et al.
Publicado: (2022)

Rituximab Therapy for Refractory Autoimmune Thrombocytopenia in Patients with Systemic Lupus Erythematosus
por: Atay, Didem, et al.
Publicado: (2012)

Steroid-Resistant Autoimmune Thrombocytopenia in Systemic Lupus Erythematosus Treated with Rituximab
por: Sardesai, Vasudha V, et al.
Publicado: (2015)

The presence of lupus nephritis additionally increases the risk of preeclampsia among pregnant women with systemic lupus erythematosus
por: Bremme, Katarina, et al.
Publicado: (2021)

Rituximab therapy for juvenile-onset systemic lupus erythematosus
por: Nwobi, Obioma, et al.
Publicado: (2007)

Rituximab reduces the hospitalization in patients with systemic lupus erythematosus
por: Martínez-Pérez, R, et al.
Publicado: (2010)

Comment on: Sudanese and Swedish patients with systemic lupus erythematosus, immunological and clinical comparisons: reply
por: Elbagir, Sahwa, et al.
Publicado: (2020)

Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy
por: Parodis, Ioannis, et al.
Publicado: (2015)

The role of herpesvirus 6A and 6B in multiple sclerosis and epilepsy
por: Dunn, Nicky, et al.
Publicado: (2020)

Neonatal lupus erythematosus—a rare syndrome of transient autoimmunity
por: Zdraveska, Nikolina, et al.
Publicado: (2022)

Analysis of rituximab’s usage for the treatment of pediatric systemic lupus erythematosus
por: Alves, Alessandra, et al.
Publicado: (2014)

Thrombotic thrombocytopenic purpura treated with rituximab in systemic lupus erythematosus
por: Karimifar, Mansoor
Publicado: (2012)

Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
por: Bonilla-Abadía, Fabio, et al.
Publicado: (2014)

Off-label use of rituximab for systemic lupus erythematosus in Europe
por: Rydén-Aulin, Monica, et al.
Publicado: (2016)

Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus
por: Penha, Mariana Álvares, et al.
Publicado: (2018)

Proteinase 3 Autoreactivity in Anti‐Neutrophil Cytoplasmic Antibody–associated vasculitis—Immunological versus clinical features
por: Sharma, Ravi K., et al.
Publicado: (2020)

Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis
por: Hardt, Uta, et al.
Publicado: (2018)

False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases
por: Kharlamova, Nastya, et al.
Publicado: (2021)

Rituximab reduces anti-cardiolipin levels in patients with systemic lupus erythematosus
por: Martínez-Pérez, R, et al.
Publicado: (2010)

B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
por: Wiesik-Szewczyk, E, et al.
Publicado: (2012)

Use of rituximab as a treatment for systemic lupus erythematosus: retrospective review
por: Machado, Roberta Ismael Lacerda, et al.
Publicado: (2014)

Refractory Orbital Myositis in Systemic Lupus Erythematosus A Role for Rituximab
por: Rodrigues Morais, Joana, et al.
Publicado: (2021)

Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis
por: Dunn, Nicky, et al.
Publicado: (2020)

Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus
por: Ruacho, Guillermo, et al.
Publicado: (2022)

Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up
por: Gerhardsson, Jakob, et al.
Publicado: (2015)

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2017)

Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis
por: Hennessey, Ashleigh, et al.
Publicado: (2019)

Efficacy and safety of rituximab for systemic lupus erythematosus treatment: a meta-analysis
por: Wu, Shanshan, et al.
Publicado: (2020)

Successful Treatment of Urticarial Vasculitis in a Patient With Systemic Lupus Erythematosus With Rituximab
por: Alharbi, Samar, et al.
Publicado: (2020)

Off-label use of rituximab in systemic lupus erythematosus: a systematic review
por: Murray, Eleanor, et al.
Publicado: (2010)

The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
por: Abid, Naushad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_83placldm515ir2dv99i3te2dh